On July 29, 2025, Iterum Therapeutics plc's subsidiary entered a five-year manufacturing agreement with ACS Dobfar S.p.A. to produce their ORLYNVAH TM tablets, ensuring supply and regulatory compliance. The agreement includes pricing based on product type and a forecasted rolling order system.